{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Alveolar+Rhabdomyosarcoma",
    "query": {
      "condition": "Refractory Alveolar Rhabdomyosarcoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T00:17:38.958Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003745",
      "title": "Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 125,
      "start_date": "1999-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 206,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003745"
    },
    {
      "nct_id": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenal Cortical Carcinoma",
        "Alveolar Soft Part Sarcoma",
        "Central Nervous System Neoplasm",
        "Childhood Clear Cell Sarcoma of Soft Tissue",
        "Clear Cell Sarcoma of Soft Tissue",
        "Ewing Sarcoma",
        "Hepatoblastoma",
        "Hepatocellular Carcinoma",
        "Osteosarcoma",
        "Recurrent Adrenal Cortical Carcinoma",
        "Recurrent Alveolar Soft Part Sarcoma",
        "Recurrent Clear Cell Sarcoma of Soft Tissue",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Osteosarcoma",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent Thyroid Gland Medullary Carcinoma",
        "Refractory Adrenal Cortical Carcinoma",
        "Refractory Alveolar Soft Part Sarcoma",
        "Refractory Clear Cell Sarcoma of Soft Tissue",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Hepatocellular Carcinoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Renal Cell Carcinoma",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory Thyroid Gland Medullary Carcinoma",
        "Refractory Wilms Tumor",
        "Renal Cell Carcinoma",
        "Rhabdomyosarcoma",
        "Soft Tissue Sarcoma",
        "Solid Neoplasm",
        "Thyroid Gland Medullary Carcinoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 109,
      "start_date": "2017-05-18",
      "completion_date": "2026-06-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02867592"
    },
    {
      "nct_id": "NCT00331643",
      "title": "Ixabepilone in Treating Young Patients With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Alveolar Childhood Rhabdomyosarcoma",
        "Childhood Synovial Sarcoma",
        "Embryonal Childhood Rhabdomyosarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "1 Year to 35 Years"
      },
      "enrollment_count": 120,
      "start_date": "2006-04",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2014-11-14",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331643"
    },
    {
      "nct_id": "NCT02748135",
      "title": "A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)"
      ],
      "interventions": [
        {
          "name": "TB-403 20mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TB-403 50mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TB-403 100mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TB-403 175mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncurious NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-05",
      "completion_date": "2020-10-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-13",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748135"
    },
    {
      "nct_id": "NCT01532687",
      "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Alveolar Soft Part Sarcoma",
        "Adult Angiosarcoma",
        "Adult Desmoplastic Small Round Cell Tumor",
        "Adult Epithelioid Hemangioendothelioma",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Myxoid Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Peripheral Nerve Sheath Tumor",
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Adult Undifferentiated Pleomorphic Sarcoma",
        "Malignant Adult Hemangiopericytoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma AJCC v7",
        "Stage IV Adult Soft Tissue Sarcoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2012-03-13",
      "completion_date": "2019-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-09-27",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01532687"
    },
    {
      "nct_id": "NCT06625190",
      "title": "Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Rhabdomyosarcoma",
        "Synovial Sarcoma",
        "Peripheral Nerve Sheath Tumors",
        "Clear Cell Sarcoma",
        "Alveolar Soft Part Sarcoma",
        "Desmoplastic Small Round Cell Tumor",
        "Chordoma",
        "Rhabdoid Tumor",
        "Epithelioid Sarcoma",
        "Myoepithelial Tumor",
        "Osteosarcoma",
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "Miltenyi CliniMACS Prodigy ® system",
          "type": "DEVICE"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "6 Months to 25 Years"
      },
      "enrollment_count": 27,
      "start_date": "2026-02-11",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625190"
    },
    {
      "nct_id": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Alveolar Soft Part Sarcoma",
        "Childhood Angiosarcoma",
        "Childhood Epithelioid Sarcoma",
        "Childhood Fibrosarcoma",
        "Childhood Gliosarcoma",
        "Childhood Leiomyosarcoma",
        "Childhood Liposarcoma",
        "Childhood Malignant Peripheral Nerve Sheath Tumor",
        "Childhood Synovial Sarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Osteosarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 46,
      "start_date": "2012-06-18",
      "completion_date": "2014-04-01",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01614795"
    },
    {
      "nct_id": "NCT05071209",
      "title": "Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Alveolar Rhabdomyosarcoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Refractory Alveolar Rhabdomyosarcoma",
        "Refractory Ewing Sarcoma",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Elimusertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 31,
      "start_date": "2021-12-22",
      "completion_date": "2026-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05071209"
    },
    {
      "nct_id": "NCT01222715",
      "title": "Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Childhood Alveolar Rhabdomyosarcoma",
        "Childhood Pleomorphic Rhabdomyosarcoma",
        "Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Childhood Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine Tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 87,
      "start_date": "2010-10",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-05-05",
      "last_synced_at": "2026-06-26T00:17:38.958Z",
      "location_count": 163,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01222715"
    }
  ]
}